Stocks Industrials PACB
NASDAQ · IndustrialsPacific Biosciences of California, Inc. (PACB)
Pacific Biosciences of California, Inc. brought in $161.4M of revenue over the twelve months to September 30, 2026, up 4.4% from a year earlier. It posted a net loss of $131.2M. In fiscal 2025 capital spending exceeded operating cash flow by $113.9M. At September 30, 2026 it held $55.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Pacific Biosciences of California, Inc.
- Net worth
- Pacific Biosciences of California, Inc. has a market value (market cap) of $733.6M at the latest share price, and shareholders' equity of -$61.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $160M (+3.9% year on year), with a net loss of $546.4M. Over the 12 months to September 30, 2026: revenue $161.4M, net loss $131.2M.
- Cash flow
- In fiscal 2025 operations used $111.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Pacific Biosciences of California, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Pacific Biosciences of California, Inc. does
Pacific Biosciences of California, Inc. is registered with the SEC under industry code SIC 3826 (Laboratory Analytical Instruments). Its shares trade on NASDAQ under the ticker PACB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $160M | -$546.4M | -$1.82 | -$113.9M |
| 2024 | $154M | -$309.9M | -$1.59 | -$212.2M |
| 2023 | $200.5M | -$306.7M | -$1.21 | -$268M |
| 2022 | $128.3M | -$314.2M | -$1.40 | -$280M |
| 2021 | $130.5M | -$181.2M | -$0.89 | -$117.1M |
| 2020 | $78.9M | $29.4M | $0.17 | $18.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where PACB ranks in Industrials
Latest SEC filings
What Pacific Biosciences of California, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Passive stake (5% or more) SCHEDULE 13G
- November 6, 2026Passive stake (5% or more) SCHEDULE 13G
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 5.5% to $40.6M versus the same quarter last year; diluted EPS -$0.12 versus -$0.13.
- November 4, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 1.9% to $39M versus the same quarter last year; diluted EPS -$0.14 versus -$0.14.
- August 5, 2026
- July 9, 2026
- June 4, 2026
Insider trades
What the people running Pacific Biosciences of California, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $2.1M worth of shares in the last 90 days and bought none on the open market. Most of the selling (99%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 6, 2026 | Gibson James R IISee Remarks | Exercised options | 500,000 | $590K |
| October 6, 2026 | Gibson James R IISee Remarks | Soldpre-planned (10b5-1) | 661,815 | $2.1M |
| August 17, 2026 | Van Oene MarkSee Remarks | Sold | 26,911 | $30.4K |
| August 10, 2026 | Van Oene MarkSee Remarks | Received as pay | 489,130 | - |
| April 8, 2026 | Gibson ChristopherDirector | Received as pay | 57,473 | - |
| April 1, 2026 | Gibson James R IISee Remarks | Sold | 88,185 | $120.8K |
| March 3, 2026 | Gibson ChristopherDirector | Received as pay | 53,913 | - |
| March 3, 2026 | Farmer MicheleSee Remarks | Sold | 2,979 | $4.5K |
Who owns PACB
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| T. Rowe Price Associates, Inc.13G, passive | 10.8% | November 6, 2026 |
| Greg Penner13G, passive with 5 related filers | 9.9% | November 14, 2024 |
| ARK Investment Management LLC13G, passive with 1 related filers | 9.59% | August 14, 2026 |
| The Goldman Sachs Group, Inc.13G, passive with 1 related filers | 7.6% | November 9, 2026 |
| SB Northstar LP13G, passive with 2 related filers | 7.5% | November 26, 2024 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 223 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 32,339,550 | +7,072,121 |
| ARK Investment Management LLC | 29,781,416 | -6,491,872 |
| Softbank Group Corp. | 20,451,570 | 0 |
| Vanguard Capital Management LLC | 13,397,934 | +620,485 |
| Geode Capital Management, LLC | 7,606,518 | +631,252 |
| Sumitomo Mitsui Trust Group, Inc. | 6,009,715 | -1,028,272 |
| Amova Asset Management Americas, Inc. | 6,009,715 | -1,028,272 |
| State Street Corp | 5,961,175 | -160,541 |
| Point72 Asset Management, L.P. | 4,787,300 | +4,501,600 |
| Two Sigma Investments, LP | 4,242,599 | +732,986 |
| D. E. Shaw & Co., Inc. | 4,208,146 | +570,599 |
| Millennium Management LLC | 3,962,442 | -929,876 |
| Goldman Sachs Group Inc | 3,229,887 | +2,241,420 |
| Citadel Advisors LLC | 2,845,903 | +1,269,852 |
| Vanguard Portfolio Management LLC | 2,671,916 | -196,477 |
| Charles Schwab Investment Management Inc | 2,652,298 | +246,802 |
| Northern Trust Corp | 2,352,786 | +221,998 |
| Vanguard Fiduciary Trust Co | 2,187,627 | +201,144 |
| Susquehanna International Group, Llp | 2,129,263 | +410,098 |
| Longaeva Partners L.P. | 2,118,231 | new |
Insiders
5 insiders reported holding 7,788,848 shares in total, about $18.4M at the last price.
| Holder | Shares |
|---|---|
| Henry Christian OSee Remarks | 3,581,813 |
| Van Oene MarkSee Remarks | 2,705,853 |
| Gibson James R IISee Remarks | 1,083,848 |
| Farmer MicheleSee Remarks | 305,948 |
| Gibson ChristopherDirector | 111,386 |
Questions about PACB
What does Pacific Biosciences of California, Inc. do?
Pacific Biosciences of California, Inc. is a company in the Industrials sector, listed on NASDAQ as PACB. Its shares trade on NASDAQ under the ticker PACB.
What is Pacific Biosciences of California, Inc.'s net worth?
Pacific Biosciences of California, Inc. has a market value (market cap) of $733.6M at the latest share price, and shareholders' equity of -$61.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Pacific Biosciences of California, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $131.2M on revenue of $161.4M.
How much revenue does Pacific Biosciences of California, Inc. make?
Over the twelve months to September 30, 2026 Pacific Biosciences of California, Inc. reported revenue of $161.4M. That is 4.4% more than a year earlier.
When did Pacific Biosciences of California, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from November 9, 2026.
When is Pacific Biosciences of California, Inc.'s next earnings report?
Pacific Biosciences of California, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare PACB with
Follow PACB
Get an email when Pacific Biosciences of California, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Pacific Biosciences of California, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.